ArticleClinical pharmacology and therapeutics2022
The Impact of COVID-19 on the Initiation of Clinical Trials in Europe and the United States.
Article in Clinical pharmacology and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination.Human vaccines & immunotherapeutics · 2023Trial
- The evolving landscape of inflammation-related clinical trials: a 25-year registry-based network analysis from a clinical pharmacology perspective.Translational and clinical pharmacology · 2026Article
- Aggregating and analysing clinical trials data from multiple public registers using R package ctrdata.Research synthesis methods · 2026Review
- Regulatory Interactions and Learnings-RADIAL the Trials@Home Proof-of-Concept Trial on Decentralization.Clinical pharmacology and therapeutics · 2025Article
- Current landscape of innovative drug development and regulatory support in China.Signal transduction and targeted therapy · 2025Review
- A Scoping Review of Prevention Classification in Mental Health: Examining the Application of Caplan's and Gordon's Prevention Frameworks (2018-2024).Journal of prevention (2022) · 2025Article
- Characteristics of pediatric interventional drug trials registered between 2015 and 2024 on ClinicalTrials.gov.Frontiers in pediatrics · 2025Article
- Evolving perceptions of point-of-care-technologies: Results from a nationwide survey of healthcare professionals.Journal of clinical and translational science · 2025Article
- Navigating Complexities In Randomized Trials: Insights From The EMERGE Trial Amidst Pandemic And Cybersecurity Threat.HRB open research · 2025Article
- Fostering quality of life in young adults living with multiple sclerosis: a pilot study of a co-created integrated intervention.Frontiers in psychology · 2024Article
- As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022.BMJ oncology · 2024Article
- Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center.Neoplasia (New York, N.Y.) · 2023Article
- Article
- The changing landscape of clinical trials in Australia.The Medical journal of Australia · 2023Article
- Applying Systems Thinking to Inform Decentralized Clinical Trial Planning and Deployment.Therapeutic innovation & regulatory science · 2023Article
- Active Clinical Trials in Hepatic Encephalopathy: Something Old, Something New and Something Borrowed.Neurochemical research · 2023Review
- Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic.JCO oncology practice · 2023Article
- Research trends within aneurysmal subarachnoid hemorrhage from 2017 to 2021: a bibliometric study.Neurosurgical review · 2023Article
- Global Association of the COVID-19 Pandemic With Pediatric Clinical Trial Publication.JAMA network open · 2023Article
- Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has a major impact not only on public health and daily living, but also on clinical trials worldwide. To investigate the potential impact of the COVID-19 pandemic on the initiation of clinical trials, we have descriptively analyzed the longitudinal change in phase II and III interventional clinical trials initiated in Europe and in the United States. Based on the public clinical trial register EU Clinical Trials Register and clinicaltrials.gov, we conducted (i) a yearly comparison of the number of initiated trials from 2010 to 2020 and (ii) a monthly comparison from January 2020 to February 2021 of the number of initiated trials. The analyses indicate that the COVID-19 pandemic affected both the initiation of clinical trials overall and the initiation of non-COVID-19 trials. An increase in the overall numbers of clinical trials could be observed both in Europe and the United States in 2020 as compared with 2019. However, the number of non-COVID-19 trials initiated is reduced as compared with the previous decade, with a slightly larger relative decrease in the United States as compared to Europe. Additionally, the monthly trend for the initiation of non-COVID-19 trials differs between regions. In the United States, after a sharp decrease in April 2020, trial numbers reached the levels of 2019 from June 2020 onward. In Europe, the decrease was less pronounced, but trial numbers mainly remained below the 2019 average until February 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.